Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT05622253 Completed - Acne Vulgaris Clinical Trials

Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Acne erythema consists of telangiectasia and erythematous papules, without a comedo, which occurs as a result of inflammatory acne. Moreover, although acne erythema is common in acne patients, no satisfactory medical or surgical treatment is available for this condition. Some acne erythema lesions may improve with time, but the persistent acne erythema, which is experienced by most patients, is cosmetically unacceptable and leads to frustration and psychological distress.

NCT ID: NCT05584150 Completed - Acne Clinical Trials

The Benefit of a Deep Cleansing Gel in the Management of Mild to Moderate Truncal Acne

Start date: October 1, 2019
Phase:
Study type: Observational

Acne vulgaris is a chronic inflammatory disease, mainly of the face, but also of the trunk. Acne may be caused by internal and external factors. Only a very small amount of data exists concerning truncal acne. The condition affects about 9% of the population worldwide, with 50% of subjects with facial acne also presenting with truncal acne. Until recently, clinicians frequently followed the same therapeutic approach as for facial acne, with treatment adherence remaining an issue. This study assessed assessed the benefit of a cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and Lipo hydroxy acids (LHA) 0.05%, used daily for 84 days in mild to moderate truncal acne.

NCT ID: NCT05573425 Completed - Acne Scar Clinical Trials

Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars

Start date: August 22, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to compare the Efficacy of Topical Tazarotene gel 0.1% versus Microneedling in atrophic Post acne scars. All patients of age 18-40 years, with grade 2 to grade 4 facial atrophic acne scars, assessed using the Goodman and Baron qualitative global scarring grading. Group A was given daily home application of Topical Tazarotene gel 0.1% while on Group B, Microneedling monthly sessions done for 12 weeks. The results were assessed by photographs, Goodman and Baron Qualitative Acne Scars Grading system at the start and end of treatment. SPSS 21 was used for data analysis which showed comparable efficacy of daily home based application of Topical Tazarotene gel 0.1% versus Microneedling monthly sessions in Atrophic Post Acne Scars.

NCT ID: NCT05550337 Completed - Acne Vulgaris Clinical Trials

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Start date: September 19, 2022
Phase: Phase 3
Study type: Interventional

To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

NCT ID: NCT05529888 Completed - Acne Vulgaris Clinical Trials

Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.

Start date: December 15, 2020
Phase: Phase 4
Study type: Interventional

Serum homocysteine level in Acne patients before and after oral Isotretinoin and Correlation between serum level of homocysteine in acne patients before and after Oral isotretinoin treatment

NCT ID: NCT05486910 Completed - Acne Clinical Trials

Management of Side-Effects of Anti-Acne Treatment by a Cosmetic Routine

Start date: April 29, 2021
Phase:
Study type: Observational

Retinoid-based topical acne treatment may induce local tolerance issues such as erythema, dryness, stinging and burning sensations that may reduce adherence and efficacy. The tested regimen (cream and cleanser) has been specifically developed to rebalance the skin microbiome and compensate side-effects of topical treatments (hydration, skin barrier repair) together with an action on skin imperfections and marks. This open-label study was conducted in subjects aged 12 years and over with sensitive skin (>2 on a sensitivity composite score from 0-3) treated for at least one month with the fixed-dose gel combination and presenting with treatment-related skin intolerance.

NCT ID: NCT05478330 Completed - Clinical trials for Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Evaluation of Efficacy of Topical Flutamide in the Treatment of Acne Vulgaris

Start date: January 13, 2021
Phase: N/A
Study type: Interventional

From the obtained results, topical Flutamide 1% gel can be a promising, effective, and safe alternative in treating patients with acne vulgaris with minimal side effects.

NCT ID: NCT05457621 Completed - Acne Vulgaris Clinical Trials

Effectiveness and Tolerance of Effaclar Serum in Women With Mandibular Acne

Start date: January 21, 2021
Phase: N/A
Study type: Interventional

The role of "dermocosmetics" in acne management is increasingly important, as many patients and even physicians now resort to them as first-line management in mild-to-moderate acne. The aim of the study is to demonstrate the efficacy of the tested product on the appearance of acne lesions in 30 adult women suffering from acne in the mandible following an active anti-acne therapy (systemic or topical). This study includes 2 months of cosmetic treatment with EFFACLAR Ultra Concentrated Serum and one month of followup without any treatment but a moisturizer with a daily UV protection. The investigational product has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. This product is expected: - to leave the skin clean and smooth, - to help unblock pores, - to exfoliate dead skin cells and help the skin to appear smoother, softer and pore-less, - to be non-comedogenic.

NCT ID: NCT05446402 Completed - Acne Clinical Trials

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

Start date: June 15, 2022
Phase: Phase 4
Study type: Interventional

The objective of this study is to compare tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.

NCT ID: NCT05428449 Completed - Acne Vulgaris Clinical Trials

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne